DART-bid for loco-regionally advanced NSCLC
Author:
Funder
Paracelsus Medical University
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Radiology, Nuclear Medicine and imaging
Link
http://link.springer.com/content/pdf/10.1007/s00066-016-1095-4.pdf
Reference21 articles.
1. Wurstbauer K, Deutschmann H, Kopp P, Merz F, Scholler H, Sedlmayer F (2009) Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans. Radiat Oncol 4:30. doi: 10.1186/1748-717X-4-30
2. Wurstbauer K, Deutschmann H, Kopp P, Kranzinger M, Merz F, Nairz O, Studnicka M, Sedlmayer F (2010) Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy – a prospective Phase I/II trial with long-term follow-up. Int J Radiat Oncol Biol Phys 77(5):1345–1351. doi: 10.1016/j.ijrobp.2009.06.060
3. Wurstbauer K, Deutschmann H, Dagn K, Kopp P, Zehentmayr F, Lamprecht B, Porsch P, Wegleitner B, Studnicka M, Sedlmayer F (2013) DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) – a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume. Radiat Oncol 8:49. doi: 10.1186/1748-717X-8-49
4. Deutschmann H, Steininger P, Nairz O, Kopp P, Merz F, Wurstbauer K, Zehentmayr F, Fastner G, Kranzinger M, Kametriser G, Kopp M, Sedlmayer F (2008) “Augmented reality” in conventional simulation by projection of 3‑D structures into 2‑D images: a comparison with virtual methods. Strahlenther Onkol 184(2):93–99. doi: 10.1007/s00066-008-1742-5
5. Zehentmayr F, Sohn M, Exeli AK, Wurstbauer K, Troller A, Deutschmann H, Fastner G, Fussl C, Steininger P, Kranzinger M, Belka C, Studnicka M, Sedlmayer F (2015) Normal tissue complication models for clinically relevant acute esophagitis (〉/= grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid). Radiat Oncol 10:121. doi: 10.1186/s13014-015-0429-1
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy;Radiotherapy and Oncology;2023-08
2. Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung—prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT;Radiation Oncology;2022-07-07
3. Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity;Cancers;2022-06-30
4. High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC;Cancers;2022-01-23
5. Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis;Current Oncology;2021-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3